Study finds that treatment of depression can increase work productivity

 

Toronto, Canada (January 11, 2012) – A new study from the Centre for Addiction and Mental Health (CAMH) has found that employees with depression who receive treatment while still working are significantly more likely to be highly productive than those who do not. This is the first study of its kind to look into a possible correlation between treatment and productivity.

 

The study is particularly significant at a time when the Canadian economy continues to face uncertainty. Mental illness costs the Canadian economy an estimated $51 billion annually, with a third of that attributed to productivity losses.

 

Published in the current issue of the Canadian Journal of Psychiatry, the study examined data from a large-scale community survey of employed and recently employed people in Alberta.

 

People who experienced a depressive episode were significantly less likely to be highly productive, the study showed. "We expected this, as past research has found that depression has adverse effects on comprehension, social participation, and day-to-day-functioning," said Dr. Carolyn Dewa, head of CAMH’s Centre for Research on Employment and Workplace Health and lead author.

 

"What’s exciting is we found that treatment for depression improves work productivity. People who had experienced a moderate depressive episode and received treatment were 2.5 times more likely to be highly productive compared with those who had no treatment," she said. "Likewise, people who experienced severe depression were seven times more likely to be high-performing than those who had no treatment."

 

Of the 3,000 workers in the in the sample, 8.5 per cent experienced a depressive episode, representing 255 workers.

 

Though the results showed the effectiveness of treatment on work and performance, the data also showed a troubling trend. "We found that among all study participants who had been diagnosed with a severe depressive episode, 57 per cent did not receive treatment; 40 per cent of those who experienced a moderate depressive episode did not receive treatment," said Dr. Dewa. "When we look at the success of workers in the sample who received treatment while still in the workplace, it really speaks to the importance of prevention and the need for employers to facilitate treatment and support. If people are able to receive treatment early, disability leave, which costs companies $18,000 per leave, may be avoided."

 

"Stigma and discrimination have often affected people’s willingness to access to services, as has the lack of knowledge around supports available in the workplace," added Dr. Dewa. "It is crucial that employers offer mental health interventions to their employees and support them in engaging in treatment, as well as continuing to support them as they transition back into the workplace."

 

The data for this analysis was collected by the Institute for Health Economics, Alberta.

 

 

The Centre for Addiction and Mental Health (CAMH) is Canada’s largest mental health and addiction teaching hospital, as well as one of the world’s leading research centres in the area of addiction and mental health. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues.

 

CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.

 


 

Centre for Addiction and Mental Health, 11.01.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…